New contraceptive method using KLK3 inhibitors to prevent pregnancy
Disruption of semen liquefaction using specific KLK3 inhibitors as a new contraceptive
This study is exploring a new way to prevent pregnancy by using a special method that keeps semen from becoming watery, which helps sperm move; it’s designed for women looking for a non-hormonal and easy-to-use contraceptive option.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Missouri-Columbia NIH-funded |
| Lab location | 1 site (Columbia, United States) |
| Project ID | NIH-11010011 on NIH RePORTER |
What this research studies
This research investigates a novel contraceptive approach that targets the liquefaction of semen to prevent sperm from reaching the egg. By using specific inhibitors of the enzyme KLK3, the study aims to block the transition of semen from a gel-like state to a watery consistency, which is crucial for sperm motility. The goal is to develop a non-hormonal, fully reversible contraceptive option that could be particularly beneficial for women who prefer over-the-counter methods. The research builds on previous findings that demonstrated the effectiveness of serine protease inhibitors in preventing pregnancy in animal models.
Who could benefit from this research
Good fit: Ideal candidates for this research are women seeking effective contraceptive methods, particularly those who prefer non-hormonal options.
Not a fit: Patients who are not seeking contraceptive methods or those who have contraindications to using such inhibitors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide women with a new, effective, and non-hormonal contraceptive option.
How similar studies have performed: Previous research has shown success with similar approaches in animal models, indicating potential for effectiveness in humans.
Where this research is happening
Columbia, United States
- University of Missouri-Columbia — Columbia, United States (Active)
Researchers
- Principal investigator: Winuthayanon, Wipawee — University of Missouri-Columbia
- Study coordinator: Winuthayanon, Wipawee
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.